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Abstract
Graft-vs-host-disease (GvHD) is currently the main complication of allogeneic hema-
topoietic stem cell transplantation. Mortality and morbidity rates are particularly high,
especially in steroid-refractory acute GvHD (aGvHD). Immune regulatory human
bone marrow mesenchymal stromal cells (hMB-MSCs) represent a therapeutic
approach to address this issue. Unfortunately, their effect is hardly predictable
in vivo due to several variables, that is, MSC tissue origin, concentration, dose num-
ber, administration route and timing, and inflammatory status of the recipient. Inter-
estingly, human bone marrow MSC-derived extracellular vesicles (hBM-MSC-EVs)
display many of the hBM-MSC immunoregulatory properties due to their content in
paracrine factors that greatly varies according to the collection method. In this study,
we focused on the immunological characterization of hBM-MSC-EVs on their capa-
bility of inducing regulatory T-cells (T-regs) both in vitro and in a xenograft mouse
model of aGvHD. We correlated these data with the aGvHD incidence and degree
following hBM-MSC-EV intravenous administration. Thus, we first quantified the
EV immunomodulation in vitro in terms of EV immunomodulatory functional unit
(EV-IFU), that is, the lowest concentration of EVs leading in vitro to at least threefold
increase of the T-regs compared with controls. Second, we established the EV thera-
peutic dose in vivo (EV-TD) corresponding to 10-fold the in vitro EV-IFU. According
to this approach, we observed a significant improvement of both mouse survival and
control of aGvHD onset and progression. This study confirms that EVs may represent
an alternative to whole MSCs for aGvHD prevention, once the effective dose is
reproducibly identified according to EV-IFU and EV-TD definition.
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1 | INTRODUCTION
The main complication of allogeneic hematopoietic stem cell transplanta-
tion (Allo-HSCT) is graft-vs-host-disease (GvHD), a donor T-cell-mediatedGiada Dal Collo, Annalisa Adamo, and Alessandro Gatti shared first co-authorship.
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alloreactive inflammatory disease affecting 20%-70% of patients.1-4
GvHD, initially classified as acute (aGvHD) and chronic (cGvHD) on the
basis of the onset time after Allo-HSCT (aGvHD <100 days, cGvHD
>100 days), is now described according to a new scoring system based on
the clinical signs and symptoms and pathogenesis.5-8 Clinical manifesta-
tions of aGvHD involve the skin, the gastrointestinal tract, and the liver
and include maculopapular erythema, gastrointestinal symptoms (abdom-
inal cramps and diarrhea), and cholestatic hepatitis, whereas cGvHD can
virtually affect any tissue/organ.9,10 Immunosuppression with steroids is
currently the first-line therapy for aGvHD.11 However, refractoriness to
steroid-based protocols characterizes about 30% of the patients; aggres-
sive immunosuppressive treatments or anti-inflammatory agents are
effective in a variable proportion of steroid-refractory patients, but the
overall survival is generally poor, with only a few long-term survivors.12,13
Consequently, alternative approaches, such as the administration of mes-
enchymal stromal cells (MSCs), have been proposed in the last decade for
refractory aGvHD treatment.14-17 In 2004, the first successful use of
MSCs was reported in severe aGvHD treatment.14 Since then, several
clinical and preclinical studies have been performed with controversial
results due to the heterogeneity in the treatment schedules (ie, MSC con-
centration, dose number, administration route, and timing) and to other
factors, such as MSC tissue origin and inflammatory status of the recipi-
ent.17-21 Similar controversial results and side effects (eg, pulmonary
embolization) were shown by preclinical studies performed in mouse
models.22-24
Human bone marrow-derived MSCs (hBM-MSCs) are a hetero-
geneous fibroblast-like cell population, including both multipotent
stem cells with the ability to form bone, cartilage, and adipose tissue
in vitro25 and stromal cell components that regulate hematopoietic
stem cell niche through specific cell-to-cell interactions and soluble
factor release.26 In 2006, the International Society for Cell & Gene
Therapy (ISCT) established the minimal criteria to define MSCs, that
is, the ability to grow as adherent cells, the membrane surface
expression of a marker combination pattern, including CD73, CD90,
and CD105 together with the lack of CD14, CD31, CD34, CD45,
and HLA-DR expression, and the ability to differentiate into adipo-
cytes, osteoblasts, and chondrocytes.27 A general functional feature
of MSC population, both of stem cells and differentiating progeni-
tors, is the acquisition of immunomodulatory properties toward
cells of both innate and adaptive immunity, depending on the pres-
ence of inflammatory cytokines in the microenvironment, such as
interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and interleukin
(IL)-1α or β.28
The immunoregulatory functions of MSCs can be mediated not
only by direct cell-to-cell contact, but also in a paracrine manner,
mostly through the release of extracellular vesicles (EVs).29,30 EVs are
spherical membrane-coated particles consisting of a lipid bilayer sur-
rounding a glycoproteic and nucleic acid content.31 According to their
size and content, EVs are classified as microvesicles, exosomes, and
apoptotic bodies, each with different biological effects.31,32 Our group
has recently shown in vitro that hBM-MSC-EVs are capable of medi-
ating immunoregulatory effects towards different immune effector
cells (IECs) by inhibiting B- and NK-cell proliferation and increasing
CD4+ T-cell population, thus suggesting a possible involvement of
T-regulatory cells (T-regs).30,33 T-regs, a subset of CD4+ T cells
expressing the IL-2 alpha-chain-receptor (CD25) and the nuclear tran-
scription factor Forkhead box P3 (FoxP3), can suppress proliferation
and effector functions in T-, B-, NK-cells, as well as antigen-
presenting cells34; consequently, T-reg-based cell therapies could be
effective the treatment of various autoimmune diseases, including
GvHD.35 The same inflammatory cytokines that trigger immunoregu-
latory functions of hBM-MSCs and therefore hBM-MSC-EVs, such as
TNF-α and IFN-γ, also promote T-reg activation and inhibitory func-
tions, thus enhancing the protection towards GvHD-associated tissue
injury in mouse models of Allo-HSCT.36,37 Consequently, hBM-MSC-
EVs may represent a potential therapeutic tool for aGvHD treatment,
provided some safety requirements for clinical use are satisfied.38
Among them, the use of heterologous supplements for hBM-MSC cul-
ture and EV collection, such as fetal bovine serum (FBS), should be
avoided to minimize the risk of infectious contaminants, such as
mycoplasma, viruses, endotoxins, or prions.39 To this aim, human
platelet lysate (hPL) has been clinically tested for safety in many pro-
tocols of human MSC ex vivo culture and expansion.39,40 hPL contains
a wide variety of growth and angiogenic factors, including platelet-
derived growth factor (PDGF)-AA, PDGF-AB, and PDGF-BB, trans-
forming growth factor (TGF)-β1 and TGF-β2, epidermal growth factor,
vascular endothelial growth factor, basic-fibroblast growth factor,
brain-derived neurotrophic factor, and hepatocyte growth factor.40
Thus, hPL seems to be a suitable substitute of FBS, in terms of repro-
ducibility and safety, for ex vivo MSC-EV production for preclinical
and clinical purposes.39,40
After systemic injection, the half-life of circulating EVs is approxi-
mately 2 minutes, but EVs have been detected after 48 hours in lungs,
liver, spleen, and pancreas,41 thus suggesting a potential long-term
therapeutic effect once administered intravenously. On this basis, sev-
eral studies suggest a potential therapeutic role of EVs in inflamma-
tory and autoimmune diseases, such as aGvHD38; however, the lack
of standardized treatment protocols still represents a major hurdle to
clearly demonstrate the in vivo effectiveness of EV administration.
Significance statement
A number of extracellular vesicle (EV) pools have been used
in the study obtained from different donor-derived bone
marrow mesenchymal stromal cells expanded in human
platelet lysate-conditioned medium, displaying in vitro the
same reproducible immune regulatory activity, regardless of
their protein concentration. The effectiveness of these EV
pools was then tested in vivo in a xenogeneic mouse model
of severe acute graft-vs-host-disease (aGvHD). Thus, the
functional parameters were defined in vitro and in vivo to
measure and predict the capability of EVs to improve mouse
survival and control of aGvHD progression.
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In this study, we first assessed the best culture conditions to
obtain hBM-MSC-EVs by comparing cell expansion and regulatory
properties toward different IECs with either FBS- or hPL-
supplemented culture media. Then, we evaluated both in vitro and
in vivo in a mouse xenograft model of aGvHD, the therapeutic poten-
tial of hPL-hBM-MSC-EVs. Thus, we could confirm that EVs may rep-
resent a valid alternative to whole MSC administration for aGvHD
treatment. In addition, the definition of EV immunomodulatory func-
tional unit (EV-IFU) in vitro and EV therapeutic dose in vivo (EV-TD)
may help to standardize the identification of the EV effective dose for
clinical purposes.
2 | MATERIALS AND METHODS
2.1 | Cell culture
MSCs were isolated from BM aspirates of healthy donors (after
informed consent, approved by Ethical Committee of Azienda
Ospedaliera Universitaria Integrata Verona; N.1828, May 12, 2010,
“Institution of cell and tissue collection for biomedical research
in Onco-Hematology”), expanded and characterized as already
described.30,42 hBM-MSCs were cultured in a minimal essential
medium supplemented with either 10% FBS, FBS-hBM-MSCs, or
5%-8% hPL40 (first and following passages, respectively) and hepa-
rin sodium (3 IU/mL), hPL-hBM-MSCs, 1% penicillin-streptomycin,
and 2% L-Glutamine (Sigma-Aldrich). hPL was obtained from a
platelet-rich plasma pool of 15 healthy donors, following the stan-
dardized clinical-grade procedures already described (40) according
to the Italian ministerial regulation “DM November 2, 2019,” thus
minimizing the variability of the process. Samples of hPL were
stored at −80C for 16 hours, and then centrifuged twice at 4000g
for 20 minutes. Prior to medium preparation, FBS and hPL were
depleted in EVs through ultracentrifugation as previously
described.30 To avoid any contamination of serum EVs, the EV-free
medium was filtered by using a 0.2-μm filter that removes the largest
population of EVs. The absence of the smallest population of EVs
(exosomes) was evaluated by FACS, assessing the negative expression of
the well-established exosome markers in EV-depleted culture media. In
addition, the hPL-MSCs used in our work were routinely tested for
mycoplasma contamination, which was excluded. hBM-MSCs at 80%
confluence were treated (primed hBM-MSCs) or not (resting hBM-
MSCs) for 48 hours with 10 ng/mL IFN-γ and 15 ng/mL TNF-α (R&D
Systems) to induce inflammatory priming. Human peripheral blood
mononuclear cells (PBMCs) were isolated using Lymphoprep (Stemcells
Technologies) and used for IEC isolation through immunomagnetic nega-
tive selection (Miltenyi Biotec) with at least 95% cell purity. For immuno-
logical assay, IECswere activated through specific stimuli (T cells: 0.5 μg/
mL of anti-CD3 and anti-CD28 (PeliCluster); B cells: 2.5 μg/mL CPG
ODN (InvivoGen), 50 ng/mL CD40L (R&D systems), 5 μg/mL MAB
50 (R&D systems), 20 U/mL IL-2 (Miltenyi Biotec), and 2 μg/mL FAB
(IgG,IgM, IgA) (Jackson Immunoresearch); NK-cells: 100 U/mL IL-2
(Miltenyi Biotec).
2.2 | FACS analysis
The identity of hBM-MSCs was checked according to the ISCT guidelines
and characterized for the presence of mesenchymal markers, that is,
CD73-PE, CD90-PE, and CD105-PE (BD Bioscience); the absence of
endothelial and hematopoietic markers, that is, CD14-PE, CD31-PE,
CD34-PE, and CD45-PE (BD Bioscience); as well as immunological
markers, that is, HLA-ABC-PE and HLA-DR-PE (BD Bioscience). The
inflammatory immunophenotype of hBM-MSCs was established by the
detection of inflammatory markers, including CD54-PE, CD80-PE,
CD86-PE, CD106 PE, HLA-ABC-PE, HLA-DR-PE (BD Bioscience),
CD273-APC, CD274-PE, and CD279-PE (Biolegend). PBMCs were char-
acterized using CD3-FITC, CD16/56-PE, CD45-PerCP, CD19-APC,
CD4-APC-H7, and CD8-PECy7 (BD Bioscience), whereas cell viability
was assessed by using TO-PRO-3-iodide (Life Technologies) or Viobility
Fixable Dyes-V500 (Miltenyi Biotec). T-reg immunophenotype was
assessed by labeling the samples with CD3-V450, CD4-PerCP,
CD8-APC-Cy7, CD25-FITC, CD127-PE-Cy7, FoxP3-APC, Viobility Fix-
able Dyes-V500 (Miltenyi Biotec), and the experiments were performed
according to manufacturer's instructions of FoxP3 Staining Buffer Set
(Miltenyi Biotec). The gating strategy was performed on viable CD3+ and
CD4+ T cells and then on CD25+CD127low cells to define T-reg pheno-
type. All data were collected through flow cytometry (FACS Canto II, BD
Bioscience) and analyzed using FlowJo software (TreeStar).
2.3 | Proliferation and cytotoxicity assay
To study cell proliferation, activated IECs were labeled with 5 μM
carboxy-fluorescein-succinimidyl-ester (CFSE) (Life Technologies), as
previously described,43 and co-cultured with resting or primed-hBM-
MSCs for 4 days (B cells) or 6 days (T and NK cells) at the MSCs:IECs
ratio of 1:10 and 1:1 (T cells and B, NK cells, respectively). Cytotoxic-
ity was analyzed through DELFIA cell cytotoxicity kit. The experi-
ments were performed according to the manufacturer's instructions
(Perkin Elmer), using activated NK-cells for 48 hours and co-cultured
with BATDA-labeled hBM-MSCs at the NK-cells:hBM-MSCs ratios of
1:1, 5:1, 15:1, 25:1 at 37C for 3 hours. Fluorescence was measured
at 615 nm using VICTORTMX4.
2.4 | Purification, characterization, and
quantification of hBM-MSC-EVs
Following cell expansion in EV-free conditioned medium, hBM-MSC-
EVs were isolated from hBM-MSCs supernatant by ultracentrifuga-
tion, as previously described.30 EV pools were obtained by mixing EVs
isolated from 5 hPL-hBM-MSC donors, with the purpose to reduce
inter-individual variability. Isolated EVs were resuspended in
phosphate-buffered saline (PBS) and stored at −80C. EV protein
quantification was performed through BCA (bicinchoninic acid) Pro-
tein Assay (Thermo Fisher Scientific). Particle size was evaluated by
dynamic light scattering (DLS) measurements using a Zetasizer Nano
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ZS (Malvern Instruments, 4 mV He-Ne laser, l0 = 633 nm, " = 173).
The DLS method can measure particles ranging from 1 nm to 6 μm.
The eventual presence of membrane fragments with different size
and shape can be easily detected in the hydrodynamic diameter distri-
bution plots of the particle's suspension analyzed. To assess the
expression pattern of surface markers, 10 μg of EVs were analyzed
using the MACSPlex Exosome Kit (Miltenyi Biotec), a multiplex bead-
based platform allowing the detection of 37 surface epitopes. Samples
were analyzed with FACS Canto II (BD Biosciences).
2.5 | Transmission electron microscopy
Stored EV samples were thawed on ice. Ten microliters of EVs were
pipetted on an ultra-thin carbon coated copper grid (CF200H-Cu-UL,
Electron Microscopy Sciences) for 5 minutes and the excess was
removed by gentle blotting. The grid was previously treated with UV
light for 15 minutes. The grid was placed on one drop of UranyLess
solution (Electron Microscopy Sciences) for 1 second, gently blotted,
and then put on a second drop for 2 minutes. The excess of solution
was removed by blotting. The grid was air-dried. Grid was visualized
on a Morgagni 268D (FEI Philips) transmission electron microscope at
80 kV. Images were taken with MegaView G3 camera and RADIUS
software (both from EMSIS GmbH).
2.6 | Xenograft mouse model
NOD/Shi-scid/IL-2Rγnull (NOG) mice were purchased from Taconic
(Germantown, New York) and kept in pathogen-free conditions in the
animal facility of the Interdepartmental Centre of Experimental
Research Service (CIRSAL) of the University of Verona, as approved
by the Italian Minister of Health. To induce aGvHD, 1 × 106 human
PBMCs/g (PBS-only as control) were injected via tail vein into 8- to
12-week-old female mice previously irradiated with 1.2 Gy from a
137Cs source. The PBMCs derived from different batches, one for
each in vivo experiment (n = 5, from PBMCs 1 to PBMCs 5).
Mice were randomized and split into two treatment groups: (a) EV-UT
mice (untreated aGvHD mice) receiving PBS i.v. and (b) EV-TD mice
(treated aGvHD mice) receiving EV-TD i.v. at +1, +4, +7 days after
PBMC injection. Mice were monitored daily until the end of experi-
ments (day +30), evaluating the onset of aGvHD clinical symptoms,
weight loss, and overall survival. Mice were ethically euthanized when
either the weight loss was over 20% of the initial weight or the cumu-
lative clinical score was 6 (Table 1).
2.7 | Evaluation of T-cell infiltration and T-reg
induction in in vivo aGvHD model
Lung, liver, spleen, and kidney were collected from sacrificed aGvHD
mice, and dissociated with 1 mM PBS EDTA, following the manufac-
turer's instructions of gentle MACS Dissociator (Miltenyi Biotec). BM
was harvested through flushing, whereas peripheral blood (PB) was
collected from retroorbital vein in tubes with heparin or D-Phenylalanyl-
L-prolyl-L-arginine chloromethyl ketone (PPACK) (Sigma-Aldrich). PB
samples were maintained at 4C to avoid coagulation. To evaluate lym-
phocyte infiltration in mouse tissues and T-reg induction in PB, IECs and
T-regs were analyzed by FACS Canto II (BD Biosciences). Splenomegaly
wasmeasured by the caliber, on day 15 after PBMC inoculation.
2.8 | ELISA assay
PB collection through retroorbital bleeding in aGvHD mice, previously
anesthetized by isoflurane, was performed at +9 and +12 days. Plasma
samples were obtained by centrifugation for 10 minutes at 2000g.
Human cytokine levels (IFN-γ and TNF-α) in plasma samples were ana-
lyzed through Quantikine ELISA kit. The experiments were performed
according to the manufacturer's instructions (R&D Systems). The levels
of human cytokines were determined using VICTORTMX4 at 450 nm,
and the concentrations reported in pg/mL.
2.9 | Statistics and image software
Statistical analysis was performed using GraphPad Prism software
(La Jolla, California). Data were expressed as mean ± standard error
TABLE 1 Clinical scoring system used for aGvHD onset evaluation in NOG mice
Clinical score 0 0.5 1 1.5 2




Strong hunching and distinct
impaired movement
Activity Normal Less movement than
normal, easier to catch
Very little movement Animal stay still but will
move when touched
Animal has no activity also
when touched
Fur Normal Slight ruffling
on the neck




Matted Fur and color
changing (yellowing)
Notes: Clinical scoring before aGvHD mouse euthanasia. Mice were ethically euthanized before the end of the experiment (day +30) when the cumulative
clinical score was 6.
Abbreviation: aGvHD, acute graft-vs-host-disease.
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means. Student's t-test was used to compare two groups, and one-
way ANOVA followed by the Tukey's range test was applied to com-
pare multiple groups. Mann-Whitney's test was used for noncoupled,
nonparametric comparison. Differences in Kaplan-Meier survival cur-
ves were analyzed with the Log-rank (Mantel-Cox) test. P < .05 was
considered as statistically significant. Adobe Illustrator software
(Adobe Inc.) was used to perform the 2D-protocol.
3 | RESULTS
3.1 | Superiority of hPL-supplemented medium for
hBM-MSC expansion and immunoregulatory studies
In line with the literature data,44 five healthy donor-derived hBM-MSC
samples were expanded by using either FBS- or hPL-supplemented cul-
ture media until the end of the cell expansion (day 19 ± 2), and
consequently characterized according to the ISCT guidelines.27 Even
though hPL-hBM-MSCs showed a stronger expression of CD73, CD90,
and HLA-ABC compared with FBS-hBM-MSCs, immunophenotypic pat-
tern was similar for FBS- and hPL-hBM-MSCs (Figure S1A). Mesodermal
differentiation was comparable with the two culture protocols
(Figure S1B). Cell growth rate at day 19 ± 2 was higher in hPL-hBM-
MSCs, as assessed through total cell number at the first cell passage
(p1) (Figure S1C), the clonogenicity (Figure S1D), and the population dou-
bling (Figure S1E), thus confirming the superiority of the hPL-based
medium to enhance hBM-MSC expansion. At p3, both FBS- and hPL-
hBM-MSCs showed a normal karyotype (Figure S2A). Moreover, in hPL-
hBM-MSCs no significant differenceswere observed in expression levels
of some oncogenes, onco-suppressors, and cell cycle regulator genes,
such as C-MYC, hTERT, TP53, and CDKN1A, between p0 and p1. hTERT
was undetectable in the two kinds of hBM-MSCs (data not shown). After
showing that hPL-supplemented medium did not influence functional
and molecular characterization of hBM-MSCs, we focused on the
F IGURE 1 Immunomodulatory properties of hBM-MSCs expanded in hPL-based culture medium. A, FBS- and hPL-hBM-MSCs were
treated (primed hBM-MSCs) or not (resting hBM-MSCs) with IFN-γ (10 ng/mL) and TNF-α (15 ng/mL) for 48 hours. The expression of
surface markers (CD54, CD106, HLA-ABC, HLA-DR, CD274, CD273) was evaluated by FACS analysis. Results are represented as fold
change expression of each specific marker compared with isotype control. Error bars represent mean ± SEM of five independent
experiments. Mann-Whitney test was used for statistical analysis. B, Both resting and primed FBS- and hPL-hBM-MSCs were incubated at
different activated NK-cells:hBM-MSCs ratios (1:1, 5:1, 15:1, 25:1) for 3 hours. Data are represented as NK cell-specific lysis. Error bars
represent mean ± SEM of five independent experiments. Mann-Whitney test was used for statistical analysis. C, Activated IECs were co-
cultured alone or in the presence of rhBM-MSCs or phBM-MSCs for 4 days (with B-cells) or 6 days (with T- and NK-cells) at the MSCs:IEC
ratio of 1:10 and 1:1 (with T-cells and B-, NK-cells, respectively). Data are represented as percentage of relative proliferating cells. Error
bars represent mean ± SEM of five independent experiments. Mann-Whitney test was used for statistical analysis. *P < .05, **P < .01.
FBS, fetal bovine serum; hBM-MSCs, human bone marrow-derived MSCs; hPL, human platelet lysate; IECs, immune effector cells; MSCs,
mesenchymal stromal cells
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immunological properties of hPL-BM-MSCs, demonstrating that hPL-
hBM-MSCs were also capable of acquiring the inflammatory phenotype,
that is, increased expression of CD54 (I-CAM), CD106 (V-CAM), HLA-
DR (MHC-II), CD273 (PD-L2), and CD274 (PD-L1) (Figure 1A and S3A).
In addition, hPL-BM-MSCs showed higher expression of HLA-ABC
(MHC-I) following inflammatory priming (Figure 1A and S3A), compared
with FBS-hBM-MSCs. Our data demonstrated that resting-hBM-MSCs
displayed a partial sensitivity to NK cell-mediated lysis, which was
prevented by inflammatory priming, without significant differences
between FBS- and hPL-hBM-MSCs (Figure 1B), in line with previous
reports.28 We also found that resting hPL-hBM-MSCs inhibited T- and
NK-cell proliferation and showed a trophic effect toward B cells. In
contrast, both primed FBS- and hPL-hBM-MSCs inhibited more
significantly T- and NK-cell proliferation and affected B cells although
without significant differences (Figure 1C). Overall, our data showed that
hPL-based expansion protocol did not affect hBM-MSC immunological
properties and inhibitory functions, but it confers superiority in terms
of expansion yield. As we have previously demonstrated that
hBM-MSC-EVs exhibit most of the properties of hBM-MSCs,32 the
hPL-based expansion protocol was chosen to obtain hBM-MSC-EVs for
the further experiments.
3.2 | Characterization of EVs obtained from
hPL-hBM-MSCs
Considering the potential capability of serum EV to influence cell behav-
ior, we first assessed the absence of hPL-derived EVs in the EV-free
medium. With this aim, hBM-MSC-EVs were isolated as pellet by ultra-
centrifugation and were washed repeatedly with PBS to eliminate any
medium-derived protein contamination. In addition, we evaluated by
FACS analysis the expression of the well-established exosome markers
in EV-depleted and filtered hPL culture media. CD9, CD63, and CD81
resulted negative compared with hPL-MSC-EVs (Figure 2A). Our previ-
ous data showed that EVs from resting- and primed FBS-hBM-MSCs
stored at −80C maintain their integrity, as revealed by DLS profile.33 In
F IGURE 2 Size, surface marker characterization, and protein quantification of hPL-hBM-MSC-derived EVs. A, Background-corrected median
fluorescence intensity of CD9, CD63, and CD81 markers in EV-depleted medium and hPL-hBM-MSC-EVs assessed by FACS. B, Hydrodynamic
diameter distribution plots measured on EVs freshly isolated from hPL-hBM-MSCs. Exosomes are represented by the smallest sizes on the left,
ranging from 25 to 90 nm, whereas microvesicles by the largest sizes on the right, ranging from 100 to 500 nm. Error bars represent mean ± SEM
obtained from at least five measurements of six independent samples. All experiments were performed in PBS at 25C. C, Wide-field TEM image
of hPL-MSC-EVs revealing the abundance of EVs. Scale bar: 100 nm. D, Background corrected median fluorescence intensity of CD9, CD63,
CD81 markers, and corresponding isotype controls on rEVs and pEVs (n = 5 and n = 3, respectively). E, EVs were isolated from six different
treated hPL-hBM-MSCs (pEVs) or not treated (rEVs) with IFN-γ (10 ng/mL) and TNF-α (15 ng/mL) for 48 hours. Scatter plot shows the absolute
protein concentration of rEVs (on the left) and pEVs (on the right), through BCA protein assay. Error bars represent mean ± SEM obtained from at
least six independent samples. F, Background-corrected median fluorescence intensity of 36 surface epitopes on rEVs and pEVs (n = 5 and n = 3,
respectively). BCA, bicinchoninic acid; EVs, extracellular vesicles; hBM-MSCs, human bone marrow-derived MSCs; hPL, human platelet lysate;
MSCs, mesenchymal stromal cells; TEM, transmission electron microscopy
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hPL-hBM-MSC-EVs, isolated through ultracentrifugation from the
supernatant of cells cultured in EV-free conditioned medium,30 we could
recognize exosomes, ranging 25-90 nm, and microvesicles, ranging
100-500 nm (Figure 2B). To confirm the presence of EVs obtained from
cell culture media, an aliquot of resuspended hPL-MSC-EVs was visual-
ized by using transmission electron microscopy (TEM). An abundance of
particles with the expected diameter and morphology of EVs was pre-
sent (Figure 2C). The spherical appearance of these particles suggested
that they maintained their integrity following the isolation process. As
also confirmed by DLS measurements, qualitative assessment of TEM
images suggested that most of the isolated EVs fell within the exosome
size range, whereas EVs with the microvesicle size range were less fre-
quent. Both resting- (rEVs) and primed-EVs (pEVs) showed similar pro-
tein concentration according to the BCA Protein Assay (Figure 2D).
Further characterization includes the assessment of the EV surface
marker profile by using a multiplex bead-based platform (Figure S3B).
Both rEVs and pEVs were positive for the exosome markers including
CD63, CD9, and CD81 (Figure 2E). EVs were also positive for CD29,
CD44, CD105 (Figure 2F). As previously observed for FBS-hBM-MSC-
EVs,33 hPL-hBM-MSC-EVs expressed SSEA-4, an early embryonic glyco-
lipid antigen identifying the adult MSC population derived from BM,45
and CD146, characterizing a specific subpopulation of MSCs with high
therapeutic potential.46 In summary, hPL-hBM-MSC-EVs are very similar
to FBS-hBM-MSC-EVs in terms of size, surface expression markers, and
protein content, thus suggesting that hPL-supplemented medium does
not modify significantly the molecular, proteomic, and immunological
properties of hBM-MSC-EVs.
3.3 | T-reg induction mediates EV
immunomodulatory effect in vitro
The ability of hBM-MSCs to drive CD4+ T-cell functional switch
toward the T-reg phenotype (CD4+CD25+CD127lowFoxP3+) has been
previously reported.46 EV-mediated immune regulation seems to be
particularly related to reduce proliferation of B- and NK-cells, rather
than T-cell proliferation.30 However, our group has previously
described in vitro a relative increase in CD4+ T-cell population follow-
ing the co-culture with EVs.30 Here, we assessed the effect of rEVs
and pEVs on T-cells, by measuring the phenotypic switch of CD4+
T-cells toward T-regs. We tested on activated T-cells the effect of
increasing quantities of EVs, as assessed by protein concentration
F IGURE 3 In vitro assay and gating strategy to study the induction of EV-mediated T-regulatory cells. A, 2 × 105 activated T-cells were
co-cultured for 7 days in the presence or not of different amount of rEVs and pEVs in terms of protein concentration (8.5, 17, and 34 μg). Then,
T-reg induction was evaluated through FACS analysis. The histogram shows the T-reg proportion (calculated as the percentage of
CD4+CD25+CD127lowFoxP3+ cells on CD4+ cells and normalized on untreated T cells) following the treatment with rEVs and pEVs. Data were
compared using Student's unpaired t tests. Error bars represent mean ± SEM obtained from at least each measurement of three (for 8.5 μg) or
five (for 17 and 34 μg) independent experiments. *P < .05, **P < .01. B, Gating strategy for evaluating T-reg proportion in the presence or not of
rEVs and pEVs. CD3+ and the subset of CD4+ cells were gated on lymphocyte population. T-regs were defined as CD4+CD25+CD127lowFOXP3+
T-cells. The last four scatter plots show the representative percentages of T-regs, calculated on CD4+ cells, following the addition of different EV
concentrations (8.5, 17, and 34 μg). EVs, extracellular vesicles
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(0, 8.5, 17, and 34 μg), obtained from single-donor hPL-hBM-MSCs.
After 7 days of co-culture, FACS analysis demonstrated that EVs were
capable of inducing a relative increase in T-reg population (Figure 3A).
A significant increase of the proportion of T-regs was observed with
both rEVs (1.88 ± 0.09, 3.77 ± 2.35, and 4.88 ± 2.90 at 8.5, 17, and
34 μg EV protein concentration, respectively) and pEVs (1.13 ± 0.16,
3.40 ± 2.08, and 4.54 ± 2.80 at 8.5, 17, and 34 μg EV protein concen-
tration, respectively) compared with the control (activated T-cells
without EV addition—0 μg EVs) (Figure 3A). Notably, despite the
increasing EV concentration, T-reg induction reached a plateau at
around threefold increase. These findings suggest that T-reg induction
plays a role in the immune regulatory effect of EVs on T-cells, and a
cutoff value of threefold increase of T-reg population may be used
in vitro as surrogate of EV immunological activity.
3.4 | Standardization of aGvHD mouse model to
assess in vivo the effectiveness of EV administration
Before performing in vivo experiments, we determined by FACS
analysis, a median composition of each PBMC batch, with the
following results: 81% ± 9% for T-cells, 5.5% ± 3.5% for B-cells, and
9% ± 4% for NK-cells, as expected in healthy donors (Figure S4A).
Activated T-cells showed a proliferation rate over 90% compared
with unstimulated PBMCs, as assessed by CFSE assay (Figure S4B).
Based on these in vitro data, NOG mice were treated with sublethal
total body irradiation (TBI) and intravenously injected with human
PBMCs, as described above. Mice were then individually scored
twice a week according to three clinical parameters (posture, activ-
ity, fur) on a scale ranging from 0 to 2 (Table 1). Figure 4A
summarizes the relative weight loss following PBMC inoculation
until day +30, compared with the control group (PBS-only mice).
Acute GvHD started at day +9 in aGvHD mouse group (PBMCs 1-5),
whereas control mice showed rapid weight recovery and then pro-
gressive gain until the end of the experiment (Figure 4A). A signifi-
cant mortality rate occurred in aGvHD mice between days +12 and
+17, particularly at days +13/+14, when the maximum aGvHD clini-
cal score was observed (Figure 4B). A significant infiltration of
human CD45+ cells, mostly CD3+ T-cells, was revealed in aGvHD
mouse organs and tissues (BM, lung, liver, spleen, kidney, PB) by
FACS analysis and immunohistochemistry (Figure 4C and Figure 5A).
Remarkably, spleen size was significantly increased in aGvHD mice
F IGURE 4 Grading of aGvHD mouse model. A, Weight change curves of aGvHD mice (PBMCs 1-5, n = 5) and control mice (PBS-only, n = 5).
Data were compared using Student's unpaired t tests and multiple t tests. B, Kaplan-Meier survival curves of aGvHD mice (PBMCs 1-5, n = 5) and
control mice (PBS-only, n = 5). Log-rank (Mantel-Cox) test was used for statistical analysis. ****P < .0001. Data were obtained with five
independent experiments. C, Human infiltrating cells (left) in different mouse target organs (n = 5). Data are represented as the percentage of
human (hCD45+) cells on total CD45+ cells including mouse cells (hCD45+ and mCD45+ cells). Error bars represent mean ± SEM of three
independent experiments. Human infiltrating T-cells (right) in different mouse target organs (n = 5). Data are represented as percentage of hCD3+
cells on hCD45+ cells. Error bars represent mean ± SEM of three independent experiments. aGvHD, acute graft-vs-host-disease; PBS, phosphate-
buffered saline; PBMCs, peripheral blood mononuclear cells
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compared with control (Figure S4C). Immunohistochemistry analysis
displayed a less broad T-cell infiltration in skin and small intestine,
whereas in the liver, portal lymphocytic infiltration, endotheliosis,
hepatocyte apoptosis, and biliary duct, damages were evident
(Figure 5A). The histopathologic score was used to quantify aGvHD
severity (Table 2) since the parameters described in Table 3. All these
data confirmed that our mouse model mimic human severe aGvHD
in a reproducible manner.
3.5 | Definition of in vitro EV-IFU and in vivo
EV-TD of hPL-hBM-MSC-derived EVs
On the basis of in vitro data (Figure 3A) and the absence of significant
differences between rEVs and pEVs, particularly as far as T-reg induc-
tion is concerned (Figure 3A), we tried to identify a reproducible
approach to define the EV-IFU capable of producing a significant immu-
nomodulatory effect in vitro. To reduce the intrinsic variability of
single-donor EVs, we adopted an EV-pooling approach by isolating and
pooling rEVs from five donor-hPL-hBM-MSCs cultured in the EV-free
conditioned medium.30 Next, we analyzed the capabilities of EV pools
to promote T-reg induction in the same condition of protein concentra-
tion, as described above (0, 8.5, 17, and 34 μg) with single donor rEV
(Figure 3A). According to our in vitro data on T-reg induction EVs
(Figure 3A), we defined EV-IFU as the lowest concentration of each
rEV-pool leading in vitro to at least threefold increase of T-regs com-
pared with controls. In other words, we assumed that different rEV
pools from different donors may have the same EV-IFU, and therefore
the same reproducible immune regulatory activity, although their pro-
tein concentration is different, thus focusing our selection on biological
effects rather than protein concentration. Accordingly, we identified
three suitable rEV-pools displaying EV-IFU (1 with 17 μg and 2 with
34 μg proteins each). They were subsequently used for in vivo experi-
ments in aGvHDmice (Figure 6A, red dots).
To assess the therapeutic efficacy of the rEV-pools in vivo, a total
dose equal to 10-fold the in vitro EV-IFU was split into three different
doses and administered to aGvHD mice at day +1, +4, and +7, thus
representing the EV-TD. Mice injected with human PBMCs to induce
F IGURE 5 Histopathological evaluation of mouse tissues. Tissues from aGvHD or control (CTRL) mice (lung, liver, spleen, intestine, skin, and
kidney) were fixed and stained with Hematoxylin and Eosin or anti-hCD3 to evaluate tissue damage and T-cell infiltration, respectively. Black
arrow A = apoptosis, red arrow B = biliary damage, arrow green P = portal infiltrate, blue arrow E = endotheliitis. Scale bars: Low magnification
200 μm; high magnification 50 μm. aGvHD, acute graft-vs-host-disease
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aGvHD and treated with EV-TD (EV-TD mice) were compared with
controls, that is, untreated aGvHD mice (EV-UT mice) receiving three














































































































































































































































































































































TABLE 3 Histologic scoring (0-4) of lung, liver, spleen, kidney,
skin, and intestine of aGvHD mice based on histopathological





Inflammation 0 No infiltration
1 Sporadic or <5% infiltration
2 Mild infiltration of 5%-25%
3 Moderate infiltration of 25%-50%
4 Severe infiltration of >60%
Liver Portal infiltrate 0 None
1 Mild, some, or all portal areas
2 Moderate, some, or all portal areas
3 Moderate/marked, all portal areas
4 Marked, all portal areas
Biliary damage 0 Absent
1 Minimal
2 Mild and diffuse
3 Moderate
4 Severe with new small bile duct
present in all portal area
Centrilobular vein
endotheliitis
0 Normal (occasional lymphocytes
around portal triads are
acceptable)
1 Rare (1-2/0.5 cm) focal collections
of mononuclear cells in
parenchyma)
2 Endotheliosis present in one
vessel/0.5 cm (subendothelial
infiltrate of a depth at least two
cells in one vessel)
3 Endotheliosis present in >3
vessels/0.5 cm with the
infiltrating depth >3 cells
4 Endotheliosis as above present in
virtually all vessels
Apoptosis 0 Absent
1 Minimal (<2 foci 10×)
2 Moderate (2–4 foci 10×)
3 Severe (>5 foci 10×)








3 Severe without ulceration
4 Severe, with ulceration
Abbreviation: aGvHD, acute graft-vs-host-disease.
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CD4+, and CD8+ T-cells in mouse PB as well as at day +9 the plasma
levels of human cytokines, such as TNF-α and IFN-γ, were measured.
We then monitored aGvHD onset and progression through several clini-
cal parameters (Table 1), weight loss, and overall survival. Such therapeu-
tic schedule significantly improved the overall survival of EV-TD mice
compared with EV-UT mice (Figure 7A); none of the EV-UT mice sur-
vived beyond day +17, whereas EV-TD mice were still alive until day
+28 (Figure 7A). In addition, EV-TD administration hampered significantly
the onset of aGvHD clinical signs, reducing the weight loss (11.5% in the
EV-TD mice vs 19.5% in EV-UT mice at day +13, **P < .01) (Figure 7B).
No significant changes were observed in the histopathologic score of the
EV-TD mouse organs compared with the EV-UT ones (data not shown).
These findings are in line with those recently shown by other authors47
and are related to the short follow-up of the experimental plan that was
mainly aimed at quantifying reproducibly the effectiveness of EV admin-
istration schedule. Nevertheless, i.v. administration of EV-TD was associ-
ated with the temporary increase of circulating T-regs as well as of the
plasmatic levels of TNF-α and IFN-γ, that is, the cytokine involved in
both EV immunomodulation48,49 and T-reg expansion.50 In fact, at day
+9, that is, 2 days after the administration of the last dose of EV-TD,
T-regs were significantly increased in PB of EV-TD compared with EV-
UT mice, whereas at day +12, the two groups showed similar T-reg levels
(Figure 7C). In addition, at day +9, the plasma levels of human TNF-α
and, IFN-γ were significantly increased in EV-TD mice compared with
EV-UT mice (TNF-α: 67.45 ± 24.01 pg/mL in EV-TD mice vs 39.55 ±
15.36 pg/mL in EV-UT mice; IFN-γ: 7.43 ± 2.86 pg/mL in EV-TD mice
vs 5.21 ± 1.12 pg/mL in EV-UT mice, respectively) (Figure 7D). Nonethe-
less, i.v. administration of EV-TD was associated to a nonsignificant mod-
ulation of circulating CD4+ and CD8+ T-cells (CD3+CD4+: 1.33 ± 1.28
and 1.18 ± 0.9, CD3+CD8+: 0.83 ± 0.55 and 0.93 ± 0.85 at days 9 and
12, respectively) (Figure S5).
4 | DISCUSSION
In 2014 a compassionate case of severe therapy-refractory aGvHD,
affecting about 30% of the Allo-HSCT patients, was treated with
MSC-derived EVs of four different BM-unrelated donors. The patient
recovered within a few months after repeated treatments, suggesting
that MSC-derived EVs could provide a potential cell-free and safe tool
to treat severe aGvHD and other inflammatory diseases.51 Further
evidence of aGvHD improvement following therapeutic infusion of
hBM-MSC-EVs, possibly due to their peculiar microRNA profiles, was
recently published,47 suggesting that hBM-MSC-EVs represent a
potential answer for important issues related to MSC clinical use. In
fact, although MSCs have been proven to be effective in treating
refractory aGvHD,15 their immune regulatory properties are hardly
predictable in vivo for several intrinsic and extrinsic reasons. Different
MSC tissue origin, concentration, dose number, administration route,
and timing as well the inflammatory status of the recipient may lead
to opposite results in terms of efficacy, thus questioning in some
cases the validity of their clinical use.52,53
Conversely, the use of MSC-derived EVs to prevent and treat
steroid-refractory aGvHD provides several potential advantages com-
pared with whole MSC administration.38 Although they contain high
concentrations of proteins and nucleic acids, including DNA and dif-
ferent RNA types, acting as powerful regulators of many cell func-
tions, EVs are cell particles devoid of autonomous replication and
therefore of neoplastic transformation risk.29 In addition, EVs can be
sterilized by filtration due to their small size and, theoretically, it is
possible to harvest EVs even from supernatants of immortalized MSC
cell lines, which otherwise could not be used for cellular therapies.51
Thus, the regulatory issues to produce EVs for clinical purposes can
be less complicated than for any other cellular strategy based on
ex vivo cell expansion and systemic administration into patients.51
Unfortunately, so far, the main challenge remains the precise
characterization of the therapeutic EV content as well as the defini-
tion of the effective EV dose before infusion to predict the clinical
benefit with good approximation. Even though hBM-MSC-EVs display
many of the BM-MSC immune regulatory properties, their content in
paracrine factors greatly varies according to the techniques used for
EV separation and the activation status of MSCs.31,32 Differential
ultracentrifugation (with or without immunomagnetic selection) is
commonly used to characterize all the EVs released by MSCs, includ-
ing small and large vesicles, and to obtain a final product devoid of
additional chemicals that could influence both functional studies and
clinical application.54 Several other EV-selecting platforms have been
developed, such as immunomagnetic exosome RNA analysis, miniatur-
ized micro-nuclear magnetic resonance microfluidic chip system,
Exochip, label-free high-throughput nano-plasmonic exosome assay
using surface plasmon resonance and other procedures. Nevertheless,
most of the studies on the EV biological activities are still based on
indirect in vitro evidence, especially in the context of the immune sys-
tem.32 This issue has triggered many different attempts to define reli-
able assays for characterizing the functionality of MSC-EV
preparations prior to administration into patients.37
F IGURE 6 Definition of therapeutic protocol for in vivo
experiments. Representative graph to define the in vitro EV-IFU:
2 × 105 activated T-cells (0.5 μg/mL anti-CD3 and 0.5 μg/mL anti-
CD28 antibodies) were co-cultured for 7 days with different rEV-
pools at three different EV concentrations (8.5, 17, and 34 μg). The
red spots display the rEV-pools increasing at least threefold the
number of T-regs compared with the control (activated T-cells
without EV addition, 0 μg of rEV-pool). These three suitable rEV-
pools (one with 17 μg and two with 34 μg proteins each) were then
used for in vivo experiments in aGvHD mice. Error bars represent
mean ± SEM of three independent experiments. aGvHD, acute graft-
vs-host-disease; EV, extracellular vesicle; EV-IFU, EV
immunomodulatory functional unit
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In this study, we established a simple method to characterize repro-
ducibly the EV immune regulatory activity according to their capability to
induce in vitro and in vivo a specific immunological effect that is impor-
tant for aGvHD amelioration, that is, T-reg induction,55 rather than on
the basis of their protein content and concentration. In fact, the simple
protein quantification does not reflect the measurable biological effects,
because the protein content may vary qualitatively according to many
factors related to donor or expansion procedures. This evidence explains
the resulting heterogeneity described in the literature. Therefore, consid-
ering the well-known limitations of considering only protein concentra-
tion for EVs quantification, we suggested a more reliable method of EV
quantification by combining their protein concentrationwith a biomarker
of their biological activity (T-reg induction). We found that this immuno-
modulatory mechanism is displayed by both rEVs (from resting hPL-BM-
MSCs) and pEVs (from inflammatory-primed hPL-BM-MSCs), even
though their surface epitopes are differentially expressed and their pro-
tein content does not vary significantly. In other words, we focused our
attention only on EV biological effects by assuming that different rEV-
pools from different donors may have the same reproducible immune
regulatory activity, although their protein concentrationmay be different
due to the intrinsic variability of single-donor EVs. To this aim, we chose
some experimental approaches that have been standardized: (i) we
adopted an EV-pooling protocol by isolating rEVs through ultracentrifu-
gation from five donor-hPL-hBM-MSCs cultured in EV-free conditioned
medium, rather than using a fixed protein concentration of single-donor
hBM-MSC-EVs; (ii) we previously assessed that the EVs used for in vitro
and in vivo immunological assays were from hBM-MSCs that were
proved effective in vitro in terms of IEC inhibition and T-reg induction.
Therefore, we eventually chose and characterized hPL-hBM-MSC-EVs,
due to the advantages in terms of MSC expansion yield and safety with
the same immunoregulatory properties; (iii) we developed a very effi-
cient xenogeneic NOG mouse model capable to mimic human severe
aGvHD in a reproducible manner, with the maximum aGvHD clinical
score at days +13/+14, easily measurable by both clinical and
F IGURE 7 Monitoring the effect of EV treatment in vivo. A, Kaplan-Meier survival curves of EV-UT mice (untreated aGvHD mice, n = 6) and
EV-TD mice (aGvHD mice treated with EV-TD, n = 8). Log-rank (Mantel-Cox) test was used for statistical analysis. Data were obtained with three
independent experiments. B, Weight change curves of control mice (PBS-only, n = 1), EV-UT mice (untreated aGvHD mice, n = 8) and EV-TD
mice (aGvHD mice treated with EV-TD, n = 10). Data were compared using Student's unpaired t tests and multiple t tests. Error bars represent
mean ± SEM obtained from five independent experiments. C, Peripheral blood T-reg evaluation was performed after 9 and 12 days from PBMC
inoculation in the aGvHD mouse model. EV-TD mice (n = 3) were treated three times (day +1, +4 and + 7) with EV-TD; EV-UT mice (n = 3)
received only vehicle (PBS). FACS analysis was performed by CD4+CD25+CD127lowFOXP3+ gating on T-cells. Error bars represent mean ± SEM
obtained from three independent experiments. Data were compared using Student's unpaired t tests. D, Quantikine ELISA was performed on
plasma samples at +9 days from PBMC inoculation into aGvHD mouse model (EV-UT and EV-TD, n = 5 each). Error bars represent mean ± SEM
obtained from at least five measurements of independent samples. Data were compared using Student's unpaired t tests. *P < .05, **P < .01.
aGvHD, acute graft-vs-host-disease; EV, extracellular vesicle; EV-TD, EV treated; EV-UT, EV-untreated; PBS, phosphate-buffered saline; PBMCs,
peripheral blood mononuclear cells
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histopathological parameters, and the maximum mortality rate between
day +12 and +17.
We then applied the above-mentioned strategy and read-out to
assess in vitro and in vivo the effectiveness of the use of hPL-hBM-
MSC-derived rEV-pools. Thus, we could first quantify reproducibly
the rEV-pool immunomodulatory effect in vitro in terms of EV-IFU.
This was the prerequisite to select only those EV pools mediating the
beneficial effect, regardless of their protein concentration and
according to the results obtained with single donor-derived hPL-hBM-
MSC-EVs showing at least threefold T-reg increase compared with
controls. Consequently, we could establish empirically the EV-TD
corresponding to 10-fold the in vitro EV-IFU, taking into consideration
that many interfering factors following EV administration in vivo may
influence and bias the final clinical effect in patients (drug interactions,
inflammatory status, lymphocytopenia, concomitant infections, etc).
According to this approach, we observed a significant improvement of
both mouse overall survival and aGvHD amelioration in terms of clini-
cal scores. As expected,47 the short follow-up did not allow us to find
significant differences in terms of histopathological score; neverthe-
less, we observed the parallel increase of some biomarkers, such as
circulating T-regs and plasmatic cytokines playing a role in T-reg
induction and EV immunomodulation (TNF-α and IFN-γ).48,55,56
5 | CONCLUSION
In summary, our mouse model of aGvHD suggests that EVs may rep-
resent a safe and valid alternative to whole MSCs for patients with
steroid-refractory aGvHD. The effective dose of EV pools is reproduc-
ibly identified according to EV-IFU and EV-TD definition, with a num-
ber of advantages in terms of patient's safety, availability,
quantification of biological effects, and reproducibility. An administra-
tion schedule based on repeated administration EV-TD and with a
longer follow-up will help to clarify the clinical impact of this experi-
mental approach in aGvHD also in terms of prevention of histopatho-
logical damages and long-term survival.
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